industry news
Subscribe Now

Qorvo Biotechnologies Omnia™ SARS-CoV-2 Antigen Test Platform Validated in National Institutes of Health (NIH) Funded Study

Independent study is an important step in verifying the quality of the Qorvo Omnia Antigen Test for use

GREENSBORO, N.C., July 28, 2021 (GLOBE NEWSWIRE) — Qorvo® (Nasdaq: QRVO), a leading provider of innovative radio frequency (RF) solutions that connect the world, announced that the Qorvo Omnia™ SARS-CoV-2 Antigen Test platform completed a key milestone for the NIH Rapid Acceleration of Diagnostics (RADxSM) initiative. Atlanta’s Center for Microsystems Engineered Point-of-Care Technologies (ACME-POCT) completed two independent studies, an adult study and a pediatric study, verifying the low SARS-CoV-2 limit of detection (LOD) and high specificity/sensitivity of the Qorvo Omnia Antigen Test.

The adult and pediatric studies compared performance of the platform to the Roche cobas 6800 (1800 NDU/ml using FDA reference panel) and Hologic Panther (600 NDU/ml) RT-PCR systems, respectively. The studies demonstrated 100% sensitivity/specificity for the adult population, and 83% sensitivity and 100% specificity for the pediatric group. Three pediatric samples that tested negative on the Qorvo Omnia Antigen Test had Cycle threshold (Ct) values greater than 38 on the Hologic system, indicating very low viral loads in those samples. Sensitivity and specificity for the study were 100% below those levels. Overall, the investigators found the Qorvo Omnia platform design intuitive and easy to use while producing rapid test results compared to high-sensitivity molecular testing systems, with test results within 20 minutes from sample collection.

James Klein, president of Qorvo Biotechnologies, said, “Independent external studies are a critical step in educating the market about the capabilities of the Omnia Antigen Test and an important milestone in the evolution of the Qorvo Omnia diagnostic platform. We are pleased with the results and investigator feedback from these studies.”

For more information, visit www.qorvobiotech.com.

This project has been funded in part by the NIH Rapid Acceleration of Diagnostics (RADxSM) initiative with federal funds from the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health. The current contract (75N92021C00008) is funded from the Public Health and Social Services Emergency Fund through the Biomedical Advanced Research and Development Authority, HHS Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services.

The Qorvo Omnia Antigen Test was granted emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) in April 2021.The test is authorized for the qualitative detection of nucleocapsid viral antigens from SARS-CoV-2 in nasal swab specimens from individuals who are suspected of having COVID-19 by their healthcare provider within the first 6 days of symptom onset.

The Qorvo Omnia platform represents a paradigm shift in diagnostic testing capability by using high frequency Bulk Acoustic Wave (BAW) sensors to achieve rapid SARS-CoV-2 (COVID-19) antigen testing. BAW sensor technology enables low LOD levels that are similar to molecular testing capability.

The Qorvo Omnia SARS-CoV-2 Antigen Test has not been FDA cleared or approved. It has been authorized by the FDA under an Emergency Use Authorization and testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform moderate or high complexity tests. This test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. Tests receiving authorization under EUA are authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

About Qorvo Biotechnologies
Qorvo Biotechnologies, LLC is a wholly owned subsidiary of Qorvo, Inc. focused on the development of point-of-care (POC) diagnostics solutions leveraging Qorvo’s innovative BAW sensor technology.

About Qorvo
Qorvo (Nasdaq: QRVO) makes a better world possible by providing innovative radio frequency (RF) solutions at the center of connectivity. We combine product and technology leadership, systems-level expertise, and global manufacturing scale to quickly solve our customers’ most complex technical challenges. Qorvo serves diverse high-growth segments of large global markets, including advanced wireless devices, wired and wireless networks, and defense radar and communications. We also leverage unique competitive strengths to advance 5G networks, cloud computing, the Internet of Things, and other emerging applications that expand the global framework interconnecting people, places and things. Visit www.qorvo.com to learn how Qorvo connects the world.
Qorvo is a registered trademark of Qorvo, Inc. in the U.S. and in other countries.

Leave a Reply

featured blogs
Sep 20, 2021
The Cadence Scholarship Program is the flagship CSR program of Cadence India, introduced five years ago. Many meritorious students from under-served sections of society drop out of the education... [[ Click on the title to access the full blog on the Cadence Community site. ...
Sep 18, 2021
Projects with a steampunk look-and-feel incorporate retro-futuristic technology and aesthetics inspired by 19th-century industrial steam-powered machinery....
Sep 15, 2021
Learn how chiplets form the basis of multi-die HPC processor architectures, fueling modern HPC applications and scaling performance & power beyond Moore's Law. The post What's Driving the Demand for Chiplets? appeared first on From Silicon To Software....
Aug 5, 2021
Megh Computing's Video Analytics Solution (VAS) portfolio implements a flexible and scalable video analytics pipeline consisting of the following elements: Video Ingestion Video Transformation Object Detection and Inference Video Analytics Visualization   Because Megh's ...

featured video

Maxim Integrated is now part of Analog Devices

Sponsored by Maxim Integrated (now part of Analog Devices)

What if we didn’t wait around for the amazing inventions of tomorrow – and got busy creating them today?

See What If: analog.com/Maxim

featured paper

Choose a high CMTI gate driver that cuts your SiC switch dead-time

Sponsored by Maxim Integrated (now part of Analog Devices)

As GaN and SiC FETs begin to replace MOSFET and IGBT technologies in power switching applications, this Maxim paper discusses the key considerations when selecting an isolated gate driver. The paper explains the importance of CMTI and propagation delay skew and presents an isolated gate driver IC ideal for use with these new power transistors.

Click to read more

featured chalk talk

The Gateway to Connected Intelligent Vehicles

Sponsored by Mouser Electronics and NXP Semiconductors

Connectivity is going to play a vital role in the future of connected and autonomous vehicles. One of the keys to the success of our future automotive designs will be the incorporation of service-oriented gateways. In this episode of Chalk Talk, Amelia Dalton chats with Brian Carlson from NXP about the role that service-oriented gateways will play in the future of connected and autonomous vehicles and the details of NXP’s new S32G2 vehicle network processors that are going to make all of this possible.

Click here for more information about the NXP Semiconductors S32G2 Vehicle Network Processor